Sophiris Bio (SPHS) Earning Somewhat Positive News Coverage, Report Shows
News headlines about Sophiris Bio (NASDAQ:SPHS) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sophiris Bio earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.657624883346 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news stories that may have effected Accern’s rankings:
- Contrasting Sophiris Bio (SPHS) & Its Rivals (americanbankingnews.com)
- Sophiris Bio (SPHS) versus Amicus Therapeutics (FOLD) Critical Comparison (americanbankingnews.com)
- Zacks: Analysts Anticipate Sophiris Bio, Inc. (SPHS) to Post -$0.11 Earnings Per Share (americanbankingnews.com)
- Analyzing Sophiris Bio (SPHS) and The Competition (americanbankingnews.com)
A number of equities research analysts have commented on the company. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Sophiris Bio in a report on Friday, September 15th. Maxim Group set a $6.00 target price on Sophiris Bio and gave the company a “buy” rating in a report on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $6.25.
Shares of Sophiris Bio (SPHS) opened at $2.06 on Monday. Sophiris Bio has a fifty-two week low of $1.80 and a fifty-two week high of $3.24. The company has a current ratio of 13.37, a quick ratio of 13.37 and a debt-to-equity ratio of 0.60.
COPYRIGHT VIOLATION WARNING: “Sophiris Bio (SPHS) Earning Somewhat Positive News Coverage, Report Shows” was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://theolympiareport.com/2017/11/20/sophiris-bio-sphs-earning-somewhat-positive-news-coverage-report-shows.html.
About Sophiris Bio
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.